Further studies on CYP21A2 pathogenic variants and polymorphisms modulating adrenal steroidogenesis in different ethnic groups might help explain the PCOS phenotype heterogeneity and variable metabolic risks, which is a prerequisite for developing more specific therapeutic approaches. This evidence concerns the gene CYP21A2 and polycystic ovary syndrome.